Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus serotype 2 (PV2) is one of the three serotypes of poliovirus, a member of the Enterovirus C species within the Picornaviridae family. Like all polioviruses, PV2 is a small, non-enveloped virus with an icosahedral capsid and a single-stranded positive-sense RNA genome approximately 7,500 nucleotides in length. PV2 enters through the mouth and replicates primarily in the oropharynx and gastrointestinal tract before potentially spreading to local lymphoid tissue, bloodstream, and central nervous system (CNS). Destruction of motor neurons—especially those in anterior horn cells—can result in acute flaccid paralysis characteristic of poliomyelitis. Wild-type PV2 was declared eradicated globally; however, vaccine-derived strains can still circulate due to reversion mutations from oral polio vaccine strains (OPV). This has led to outbreaks associated with circulating vaccine-derived polioviruses type 2 (cVDPV2).
Vaccine-induced antibody neutralization of viral entry.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Serotype 2.